4//SEC Filing
COLES N ANTHONY 4
Accession 0000950170-24-081490
CIK 0001805387other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 4:05 PM ET
Size
9.4 KB
Accession
0000950170-24-081490
Insider Transaction Report
Form 4
COLES N ANTHONY
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2024-07-01$3.50/sh+25,000$87,500→ 50,928 total - Sale
Common Stock
2024-07-01$41.18/sh−25,000$1,029,535→ 25,928 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-01−25,000→ 2,177,417 totalExercise: $3.50Exp: 2028-12-24→ Common Stock (25,000 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person.
- [F2]This number includes 10,290 unvested Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. These RSUs shall vest upon the earlier of: (i) June 5, 2025, or (ii) the 2025 annual meeting of stockholders of the Company.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.85 to $41.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option is fully vested and exercisable.
Documents
Issuer
Cerevel Therapeutics Holdings, Inc.
CIK 0001805387
Entity typeother
Related Parties
1- filerCIK 0001197018
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 4:05 PM ET
- Size
- 9.4 KB